|
Mechanismβ2-adrenergic receptor agonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date04 Feb 1994 |
|
Mechanismβ2-adrenergic receptor agonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.GB |
First Approval Date29 Nov 1968 |
100 Clinical Results associated with GlaxoSmithKline Intellectual Property Ltd.
0 Patents (Medical) associated with GlaxoSmithKline Intellectual Property Ltd.
100 Deals associated with GlaxoSmithKline Intellectual Property Ltd.
100 Translational Medicine associated with GlaxoSmithKline Intellectual Property Ltd.